Gene Therapy to Target Mesothelin for Oncology is under clinical development by Shenzhen BinDeBio and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase II drugs for Metastatic Pancreatic Cancer have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gene Therapy to Target Mesothelin for Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene Therapy to Target Mesothelin for Oncology overview
Gene Therapy is under development for the treatment of metastatic pancreatic cancer, glioblastoma, liver cancer, gastric cancer and esophageal cancer. It is administered by intravenous route. The therapeutic candidate comprises autologous T cells engineered to express chimeric antigen receptor (CAR) consisting of an anti-mesothelin single chain variable fragment (scFv) and fused to co-stimulatory domain 4-1BB and TCR zeta.
For a complete picture of Gene Therapy to Target Mesothelin for Oncology’s drug-specific PTSR and LoA scores, buy the report here.